STUDI EFEKTIVITAS DAN EFEK SAMPING FAVIPIRAVIR PADA PASIEN COVID-19 PNEUMONIA DI RUMAH SAKIT BHAYANGKARA SURABAYA

Rika Yulia
Fauna Herawati (Departemen Farmasi Klinis dan Komunitas, Fakultas Farmasi, Universitas Surabaya, Surabaya Indonesia, 60293)
Klara Rosjuita Hima (Mahasiswa Program Studi Farmasi, Fakultas Farmasi, Universitas Surabaya, Surabaya Indonesia, 60293)
Ruddy Hartono (Rumah Sakit Bhayangkara Surabaya HS Samsoeri Mertojoso, Surabaya Indonesia, 60231)
Puri Safitri Hanum (Rumah Sakit Bhayangkara Surabaya HS Samsoeri Mertojoso, Surabaya Indonesia, 60231)

Jurnal Ilmiah Ibnu Sina (JIIS): Ilmu Farmasi dan Kesehatan
Vol 8 No 2 (2023): JIIS

Favipiravir's indication extended for COVID-19 disease. This background consideration is related to its mechanism of action or effectivity in some COVID-19 patients, with or without pneumonia. This research is a retrospective observational study and analysis descriptively. The research material is medical records of patients with COVID-19 pneumonia using favipiravir from December 2020-May 2021. A total of 33 samples obtained met the inclusion and exclusion criteria. Effectiveness was analyzed by calculating the percentage of COVID-19 pneumonia patients who only used favipiravir while they were being treated until the patient was discharged. The side effects were the number of COVID-19 patients who drug injury liver disease (AST and ALT increase more than three times upper limit) and neutrophenia. This study reported that favipiravir was effective in COVID-19 patients with pneumonia, seen from 78.79% of patients who only used favipiravir during treatment. There were no patients who had an increase in AST ALT >3×upper limit of normal, and only seven patients with neutropenia.